Axsome Therapeutics AXSM
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 10th percentile, 5-year average -22.1x
Around its usual level · 54th percentile, 5-year average 70.4x
#5280 of 5331 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 15th percentile, 5-year average 32.3x
#4406 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 70.70 | – | 70.38 | 54% (pricier than usual) | #5280 of 5331 (1 = cheapest) |
| PE | -46.76 | 73.82 | -22.07 | 10% (cheaper than usual) | – |
| PS | 8.61 | 5.74 | 32.25 | 15% (cheaper than usual) | #4406 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on AXSM.
Sign in to join the discussion.